了解 BRD8 在人类癌症发生中的作用。
Understanding the role of BRD8 in human carcinogenesis.
发表日期:2024 Jul 05
作者:
Kiyoshi Yamaguchi, Saya Nakagawa, Yoichi Furukawa
来源:
Epigenetics & Chromatin
摘要:
溴结构域是一种保守的蛋白质-蛋白质相互作用模块,专门识别组蛋白和其他蛋白质上的乙酰化赖氨酸残基。值得注意的是,含溴结构域的蛋白质通过招募各种转录因子和/或蛋白质复合物(例如 ATP 依赖性染色质重塑剂和乙酰转移酶)参与转录调节。含溴结构域蛋白 8 (BRD8) 是一种最初被认为是骨骼肌丰富蛋白和 120kDa 甲状腺激素受体共激活蛋白 (TrCP120) 的分子,被证明是 NuA4/TIP60-组蛋白乙酰转移酶复合物的亚基。据报道,BRD8 在一部分癌症中表达上调,并与细胞增殖的调节以及对细胞毒性药物的反应有关。然而,人们对潜在的分子机制仍知之甚少。近年来,越来越清楚的是,BRD8 的溴结构域识别乙酰化和/或非乙酰化组蛋白 H4 和 H2AZ,并且 BRD8 以 NuA4/TIP60 复合物依赖性和非依赖性方式与癌症发展相关。在这篇综述中,我们将概述目前有关 BRD8 分子功能的知识,重点关注 BRD8 溴结构域在癌细胞中的生物学作用。© 2024 作者。约翰·威利出版的《癌症科学》
The bromodomain is a conserved protein-protein interaction module that functions exclusively to recognize acetylated lysine residues on histones and other proteins. It is noteworthy that bromodomain-containing proteins are involved in transcriptional modulation by recruiting various transcription factors and/or protein complexes such as ATP-dependent chromatin remodelers and acetyltransferases. Bromodomain-containing protein 8 (BRD8), a molecule initially recognized as skeletal muscle abundant protein and thyroid hormone receptor coactivating protein of 120 kDa (TrCP120), was shown to be a subunit of the NuA4/TIP60-histone acetyltransferase complex. BRD8 has been reported to be upregulated in a subset of cancers and implicated in the regulation of cell proliferation as well as in the response to cytotoxic agents. However, little is still known about the underlying molecular mechanisms. In recent years, it has become increasingly clear that the bromodomain of BRD8 recognizes acetylated and/or nonacetylated histones H4 and H2AZ, and that BRD8 is associated with cancer development in both a NuA4/TIP60 complex-dependent and -independent manner. In this review, we will provide an overview of the current knowledge on the molecular function of BRD8, focusing on the biological role of the bromodomain of BRD8 in cancer cells.© 2024 The Author(s). Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.